Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol for Catheter Related Bladder Discomfort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age,~* American Society of Anesthesiologists (ASA) Physical Status of I-II,~* undergoing PNL with urinary bladder catheter.~Exclusion Criteria:~* obesity (BMI \> 30),~* chronic opioid use,~* bladder outflow obstruction,~* benign prostatic hyperplasia, and~* overactive bladder (OAB) (frequency \> 3 times at night or \> 8 times within 24h).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl (Type: PLACEBO_COMPARATOR): None
- Group Paracetamol(n=32):iv 15mg/kg paracetamol (Type: ACTIVE_COMPARATOR): The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was \>3.

Based on this trial design, predict the completion outcome and termination type (if applicable).